El Toro, CA, United States of America

David A Woodward


Average Co-Inventor Count = 1.1

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • El Toro, CA (US) (1991 - 1993)
  • Lake Forest, CA (US) (1998)

Company Filing History:


Years Active: 1991-1998

Loading Chart...
4 patents (USPTO):Explore Patents

Title: David A. Woodward: Innovator in Ocular Therapeutics

Introduction

David A. Woodward is a notable inventor based in El Toro, California. He has made significant contributions to the field of ocular therapeutics, holding a total of 4 patents. His work focuses on the development of innovative solutions for managing intraocular pressure.

Latest Patents

Among his latest patents, Woodward has developed formulations involving 5-trans-prostaglandins of the F series. These inventions relate to the use of derivatives of F-type prostaglandins as ocular hypotensives. The specific structure of these compounds allows for effective management of intraocular pressure, which is crucial for patients with glaucoma and other eye conditions. Another significant patent involves the use of prostaglandin F3α as an ocular hypotensive agent, providing a method and composition for reducing or maintaining intraocular pressure through the administration of a composition containing this compound in a pharmaceutically acceptable carrier.

Career Highlights

David A. Woodward is currently associated with Allergan, Inc., a leading company in the pharmaceutical industry known for its focus on eye care products. His work at Allergan has allowed him to further his research and development efforts in ocular therapeutics.

Collaborations

Woodward collaborates with Ming Fai Chan, contributing to the advancement of innovative treatments in the field of ophthalmology.

Conclusion

David A. Woodward's contributions to ocular therapeutics through his patents and work at Allergan, Inc. highlight his commitment to improving eye health. His innovative approaches continue to pave the way for advancements in the treatment of intraocular pressure-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…